Efficacy and Safety of Risedronate in Osteoporosis Subjects with Comorbid Diabetes, Hypertension, and/or Dyslipidemia: A Post Hoc Analysis of Phase III Trials Conducted in Japan

Many osteoporotics have comorbid diabetes mellitus (DM), hypertension (HT), and dyslipidemia (DL). However, whether such comorbidities alter response to anti-osteoporotic treatment is unknown. We did post hoc analyses of combined data from three risedronate Japanese phase III trials to determine whe...

Descripción completa

Detalles Bibliográficos
Autores principales: Inoue, Daisuke, Muraoka, Ryoichi, Okazaki, Ryo, Nishizawa, Yoshiki, Sugimoto, Toshitsugu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4723633/
https://www.ncbi.nlm.nih.gov/pubmed/26466937
http://dx.doi.org/10.1007/s00223-015-0071-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4723633/
https://www.ncbi.nlm.nih.gov/pubmed/26466937
http://dx.doi.org/10.1007/s00223-015-0071-9

Ejemplares similares